Transcriptional control mechanisms associated with the nucleotide receptor P2X7, a critical regulator of immunologic, osteogenic, and neurologic functions

Immunologic Research

Volumn 50, Issue 1, 2011, Pages 22-38

  Lenertz, Lisa Y ^a   Gavala, Monica L ^a   Zhu, Yiming ^a   Bertics, Paul J ^a  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

FosB; Gene transcription; Inflammation; Macrophages; Nucleotide receptors; P2X7

Indexed keywords

A 438079; ADENOSINE TRIPHOSPHATE; AFC 5128; AZD 9056; CALCIUM ION; CE 224535; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; CYCLOOXYGENASE 2; EVT 401; GSK 1482160; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 18; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 6; INTERLEUKIN 8; METHOTREXATE; MITOGEN ACTIVATED PROTEIN KINASE; PURINERGIC P2X7 RECEPTOR; PURINERGIC RECEPTOR BLOCKING AGENT; TRANSCRIPTION FACTOR AP 1; TRANSCRIPTION FACTOR FOSB; TRANSCRIPTION FACTOR NFAT; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VASCULOTROPIN;

ALLODYNIA; ALZHEIMER DISEASE; ARTHRITIS; CELL DEATH; CHRONIC OBSTRUCTIVE LUNG DISEASE; DEGENERATIVE DISEASE; DEPRESSION; DRUG EFFICACY; DRUG TARGETING; GENE EXPRESSION; GENE MUTATION; GLOMERULONEPHRITIS; HUMAN; HYPERALGESIA; IRRITABLE COLON; LIGAND BINDING; MEDIATOR RELEASE; MOOD DISORDER; NERVOUS SYSTEM INFLAMMATION; NONHUMAN; OSTEOARTHRITIS; PAIN; PRIORITY JOURNAL; PROTEIN DOMAIN; REVIEW; RHEUMATOID ARTHRITIS; SINGLE NUCLEOTIDE POLYMORPHISM; TRANSCRIPTION REGULATION;

ADENOSINE TRIPHOSPHATE; ANIMALS; BIOLOGICAL MARKERS; GENE EXPRESSION REGULATION; HUMANS; IMMUNOLOGIC FACTORS; INFLAMMATION; INTERLEUKIN-1BETA; OSTEOGENESIS; PROTO-ONCOGENE PROTEINS C-FOS; RECEPTORS, PURINERGIC P2X7; SIGNAL TRANSDUCTION;

EID: 79955625073     PISSN: 0257277X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12026-011-8203-4     Document Type: Review

References (169)

1. Burnstock G. Physiology and pathophysiology of purinergic neurotransmission. Physiol Rev. 2007;87:659-797. (Pubitemid 47084682)
2. Orriss IR, Burnstock G, Arnett TR. Purinergic signalling and bone remodelling. Curr Opin Pharmacol. 2010;10:322-30.
3. Burnstock G. Purinergic signaling and vascular cell proliferation and death. Arterioscler Thromb Vasc Biol. 2002;22:364-73. (Pubitemid 34218740)
4. Ralevic V, Burnstock G. Receptors for purines and pyrimidines. Pharmacol Rev. 1998;50:413-92. (Pubitemid 28477681)
5. Lazarowski ER, Boucher RC, Harden TK. Mechanisms of release of nucleotides and integration of their action as P2X- and P2Y-receptor activating molecules. Mol Pharmacol. 2003;64:785-95. (Pubitemid 37153046)
6. North R, Surprenant A. Pharmacology of cloned P2X receptors. Annu Rev Pharmacol Toxicol. 2000;40:563-80. (Pubitemid 30340693)
7. North R. Molecular physiology of P2X receptors. Physiol Rev. 2002;82:1013-67.
8. Guile S, Alcaraz L, Birkinshaw T, Bowers K, Ebden M, Furber M, Stocks M. Antagonists of the P2X(7) receptor. From lead identification to drug development. J Med Chem. 2009;52:3123-41.
9. Angiolillo D, Ueno M, Goto S. Basic principles of platelet biology and clinical implications. Circ J. 2010;74:597-607.
10. Abergel E, Nikolsky E. Ticagrelor: an investigational oral antiplatelet treatment for reduction of major adverse cardiac events in patients with acute coronary syndrome. Vasc Health Risk Manag. 2010;6:963-77.
11. Gunosewoyo H, Kassiou M. P2X purinergic receptor ligands: recently patented compounds. Expert Opin Ther Pat. 2010;20:625-46.
12. Lenertz LY, Gavala M, Hill LM, Bertics PJ. Cell signaling via the P2X(7) nucleotide receptor: linkage to ROS production, gene transcription, and receptor trafficking. Purinergic Signal. 2009;5:175-87.
13. Lenertz LY, Wang Z, Guadarrama AG, Hill LM, Gavala ML, Bertics PJ. Mutation of putative N-linked glycosylation sites on the human nucleotide receptor P2X(7) reveals a key residue important for receptor function. Biochemistry. 2010;49:4611-9.
14. Boumechache M, Masin M, Edwardson J, Górecki D, Murrell- Lagnado R. Analysis of assembly and trafficking of native P2X4 and P2X7 receptor complexes in rodent immune cells. J Biol Chem. 2009;284:13446-54.
15. Aga M, Johnson CJ, Hart AP, Guadarrama AG, Suresh M, Svaren J, Bertics PJ, Darien BJ. Modulation of monocyte signaling and pore formation in response to agonists of the nucleotide receptor P2X(7). J Leukoc Biol. 2002;72:222-32.
16. Bianco F, Colombo A, Saglietti L, Lecca D, Abbracchio M, Matteoli M, Verderio C. Different properties of P2X(7) receptor in hippocampal and cortical astrocytes. Purinergic Signal. 2009;5: 233-40.
17. Grol MW, Panupinthu N, Korcok J, Sims SM, Dixon SJ. Expression, signaling, and function of P2X7 receptors in bone. Purinergic Signal. 2009;5:205-21.
18. Zhou D, Chen ML, Zhang YQ, Zhao ZQ. Involvement of spinal microglial P2X7 receptor in generation of tolerance to morphine analgesia in rats. J Neurosci. 2010;30:8042-7.
19. Ferrari D, Chiozzi P, Falzoni S, Dal Susino M, Melchiorri L, Baricordi O, Di Virgilio F. Extracellular ATP triggers IL-1 beta release by activating the purinergic P2Z receptor of human macrophages. J Immunol. 1997;159:1451-8. (Pubitemid 127484125)
20. Gavala ML, Hill LM, Lenertz LY, Karta MR, Bertics PJ. Activation of the transcription factor FosB/activating protein-1 (AP-1) is a prominent downstream signal of the extracellular nucleotide receptor P2RX7 in monocytic and osteoblastic cells. J Biol Chem. 2010;285:34288-98.
21. Hill LM, Gavala ML, Lenertz LY, Bertics PJ. Extracellular ATP may contribute to tissue repair by rapidly stimulating purinergic receptor X7-dependent vascular endothelial growth factor release from primary human monocytes. J Immunol. 2010;185: 3028-34.
22. Solle M, Labasi J, Perregaux DG, Stam E, Petrushova N, Koller BH, Griffiths RJ, Gabel CA. Altered cytokine production in mice lacking P2X7 receptors. J Biol Chem. 2001;276:125-32. (Pubitemid 32050297)
23. Denlinger LC, Fisette PL, Sommer JA, Watters JJ, Prabhu U, Dubyak GR, Proctor RA, Bertics PJ. The nucleotide receptor P2X7 contains multiple protein- and lipid-interaction motifs including a potential binding site for bacterial lipopolysaccharide. J Immunol. 2001;167:1871-6. (Pubitemid 32747489)
24. Fuller S, Stokes L, Skarratt K, Gu B, Wiley JS. Genetics of the P2X7 receptor and human disease. Purinergic Signal. 2009;5: 257-62.
25. Smart M, Gu B, Panchal R, Wiley J, Cromer B, Williams D, Petrou S. P2X7 receptor cell surface expression and cytolytic pore formation are regulated by a distal C-terminal region. J Biol Chem. 2003;278:8853-60.
26. Denlinger LC, Sommer JA, Parker K, Gudipaty L, Fisette PL, Watters JJ, Proctor RA, Dubyak GR, Bertics PJ. Mutation of a dibasic amino acid motif within the C terminus of the P2X7 nucleotide receptor results in trafficking defects and impaired function. J Immunol. 2003;171:1304-11. (Pubitemid 36900061)
27. Roger S, Mei ZZ, Baldwin JM, Dong L, Bradley H, Baldwin SA, Surprenant A, Jiang LH. Single nucleotide polymorphisms that were identified in affective mood disorders affect ATPactivated P2X(7) receptor functions. J Psychiatr Res. 2009;44: 347-55.
28. Gonnord P, Delarasse C, Auger R, Benihoud K, Prigent M, Cuif M, Lamaze C, Kanellopoulos J. Palmitoylation of the P2X7 receptor, an ATP-gated channel, controls its expression and association with lipid rafts. FASEB J. 2009;23:795-805.
29. Shinozaki Y, Sumitomo K, Tsuda M, Koizumi S, Inoue K, Torimitsu K. Direct observation of ATP-induced conformational changes in single P2X4 receptors. PLoS Biol. 2009;7:e103.
30. Gavala ML, Pfeiffer ZA, Bertics PJ. The nucleotide receptor P2RX7 mediates ATP-induced CREB activation in human and murine monocytic cells. J Leukoc Biol. 2008;84:1159-71.
31. Denlinger LC, Shi L, Guadarrama AG, Schell K, Green D, Morrin A, Hogan K, Sorkness R, Busse WW, Gern JE. Attenuated P2X7 pore function as a risk factor for virus-induced loss of asthma control. Am J Respir Crit Care Med. 2009;179: 265-70.
32. Dardano A, Falzoni S, Caraccio N, Polini A, Tognini S, Solini A, Berti P, Di Virgilio F, Monzani F. 1513A[C polymorphism in the P2X7 receptor gene in patients with papillary thyroid cancer: correlation with histological variants and clinical parameters. J Clin Endocrinol Metab. 2009;94:695-8.
33. Solini A, Cuccato S, Ferrari D, Santini E, Gulinelli S, Callegari M, Dardano A, Faviana P, Madec S, Di Virgilio F, Monzani F. Increased P2X7 receptor expression and function in thyroid papillary cancer: a new potential marker of the disease? Endocrinology. 2008;149:389-96.
34. Wang X, Arcuino G, Takano T, Lin J, Peng W, Wan P, Li P, Xu Q, Liu Q, Goldman S, Nedergaard M. P2X7 receptor inhibition improves recovery after spinal cord injury. Nat Med. 2004;10: 821-7. (Pubitemid 39070855)
35. Peng W, Cotrina M, Han X, Yu H, Bekar L, Blum L, Takano T, Tian G, Goldman S, Nedergaard M. Systemic administration of an antagonist of the ATP-sensitive receptor P2X7 improves recovery after spinal cord injury. Proc Natl Acad Sci USA. 2009; 106:12489-93.
36. Dell'Antonio G, Quattrini A, Dal Cin E, Fulgenzi A, Ferrero M. Antinociceptive effect of a new P(2Z)/P2X7 antagonist, oxidized ATP, in arthritic rats. Neurosci Lett. 2002;327:87-90. (Pubitemid 34722414)
37. Broom D, Matson D, Bradshaw E, Buck M, Meade R, Coombs S, Matchett M, Ford K, Yu W, Yuan J, Sun S, Ochoa R, Krause J, Wustrow D, Cortright D. Characterization of N-(adamantan-1- ylmethyl)-5-[(3R-amino-pyrrolidin-1-yl) methyl]-2-chloro-benzamide, a P2X7 antagonist in animal models of pain and inflammation. J Pharmacol Exp Ther. 2008;327:620-33.
38. Dell'Antonio G, Quattrini A, Cin E, Fulgenzi A, Ferrero M. Relief of inflammatory pain in rats by local use of the selective P2X7 ATP receptor inhibitor, oxidized ATP. Arthritis Rheum. 2002;46:3378-85. (Pubitemid 35453550)
39. Ke H, Qi H, Weidema A, Zhang Q, Panupinthu N, Crawford D, Grasser W, Paralkar V, Li M, Audoly L, Gabel C, Jee W, Dixon S, Sims S, Thompson D. Deletion of the P2X7 nucleotide receptor reveals its regulatory roles in bone formation and resorption. Mol Endocrinol. 2003;17:1356-67. (Pubitemid 36819956)
40. Li J, Liu D, Ke HZ, Duncan RL, Turner CH. The P2X7 nucleotide receptor mediates skeletal mechanotransduction. J Biol Chem. 2005;280:42952-9.
41. Romanello M, Pani B, Bicego MD, Andrea P. Mechanically induced ATP release from human osteoblastic cells. Biochem Biophys Res Commun. 2001;289:1275-81. (Pubitemid 34076330)
42. Buckley KA, Golding SL, Rice JM, Dillon JP, Gallagher JA. Release and interconversion of P2 receptor agonists by human osteoblast-like cells. FASEB J. 2003;17:1401-10. (Pubitemid 36935655)
43. Lommatzsch M, Cicko S, Müller T, Lucattelli M, Bratke K, Stoll P, Grimm M, Dürk T, Zissel G, Ferrari D, Di Virgilio F, Sorichter S, Lungarella G, Virchow J, Idzko M. Extracellular adenosine triphosphate and chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2010;181:928-34.
44. Lucattelli M, Cicko S, Müller T, Lommatzsch M, de Cunto G, Cardini S, Sundas W, Grimm M, Zeiser R, Dürk T, Zissel G, Sorichter S, Ferrari D, Di Virgilio F, Virchow J, Lungarella G, Idzko M: P2X7 receptor signalling in the pathogenesis of smoke-induced lung inflammation and emphysema. Am J Respir Cell Mol Biol 2010.
45. Chessell I, Hatcher J, Bountra C, Michel A, Hughes J, Green P, Egerton J, Murfin M, Richardson J, Peck W, Grahames C, Casula M, Yiangou Y, Birch R, Anand P, Buell G. Disruption of the P2X7 purinoceptor gene abolishes chronic inflammatory and neuropathic pain. Pain. 2005;114:386-96. (Pubitemid 40385877)
46. Clark A, Staniland A, Marchand F, Kaan T, McMahon S, Malcangio M. P2X7-dependent release of interleukin-1beta and nociception in the spinal cord following lipopolysaccharide. J Neurosci. 2010;30:573-82.
47. Taylor S, Turner C, Elliott J, McDaid J, Hewitt R, Smith J, PickeringM,WhitehouseD,CookH,BurnstockG, PuseyC,Unwin R, Tam F. P2X7 deficiency attenuates renal injury in experimental glomerulonephritis. J Am Soc Nephrol. 2009;20:1275-81.
48. Maes M. The cytokine hypothesis of depression: inflammation, oxidative & nitrosative stress (IO&NS) and leaky gut as new targets for adjunctive treatments in depression. Neuro Endocrinol Lett. 2008;29:287-91.
49. Smith RS. The macrophage theory of depression. Med Hypotheses. 1991;35:298-306.
50. Anisman H, Merali Z, Poulter MO, Hayley S. Cytokines as a precipitant of depressive illness: animal and human studies. Curr Pharm Des. 2005;11:963-72. (Pubitemid 40331298)
51. Pollak Y, Yirmiya R. Cytokine-induced changes in mood and behaviour: implications for 'depression due to a general medical condition', immunotherapy and antidepressive treatment. Int J Neuropsychopharmacol. 2002;5:389-99.
52. Basso A, Bratcher N, Harris R, Jarvis M, Decker M, Rueter L. Behavioral profile of P2X7 receptor knockout mice in animal models of depression and anxiety: relevance for neuropsychiatric disorders. Behav Brain Res. 2009;198:83-90.
53. Sharma S, Kumar V, Khosla R, Kajal N, Sarin B, Sehajpal P. Association of P2X7 receptor +1513 (A->C) polymorphism with tuberculosis in a Punjabi population. Int J Tuberc Lung Dis. 2010;14:1159-63.
54. Xiao J, Sun L, Yan H, Jiao W, Miao Q, Feng W, Wu X, Gu Y, Jiao A, Guo Y, Peng X, Shen A. Metaanalysis of P2X7 gene polymorphisms and tuberculosis susceptibility. FEMS Immunol Med Microbiol. 2010;60:165-70.
55. Niño-Moreno P, Portales-Pérez D, Hernández-Castro B, Portales- Cervantes L, Flores-Meraz V, Baranda L, Gómez-Gómez A, Acuña-Alonzo V, Granados J, González-Amaro R. P2X7 and NRAMP1/SLC11 A1 gene polymorphisms in Mexican mestizo patients with pulmonary tuberculosis. Clin Exp Immunol. 2007; 148:469-77. (Pubitemid 46701022)
56. Tekin D, Kayaalti Z, Dalgic N, Cakir E, Soylemezoglu T, Isin Kutlubay B, Aydin Kilic B. Polymorphism in the p2x7 gene increases susceptibility to extrapulmonary tuberculosis in Turkish children. Pediatr Infect Dis J. 2010;29:779-82.
57. Fernando S, Saunders B, Sluyter R, Skarratt K, Goldberg H, Marks G, Wiley J, Britton WA. Polymorphism in the P2X7 gene increases susceptibility to extrapulmonary tuberculosis. Am J Respir Crit Care Med. 2007;175:360-6.
58. Gu B, Zhang W, Worthington R, Sluyter R, Dao-Ung P, Petrou S, Barden J, Wiley JS. A Glu-496 to Ala polymorphism leads to loss of function of the human P2X7 receptor. J Biol Chem. 2001;276: 11135-42. (Pubitemid 38089296)
59. Boldt W, Klapperstück M, Büttner C, Sadtler S, Schmalzing G, Markwardt F. Glu496Ala polymorphism of human P2X7 receptor does not affect its electrophysiological phenotype. Am J Physiol Cell Physiol. 2003;284:C749-56.
60. Cabrini G, Falzoni S, Forchap S, Pellegatti P, Balboni A, Agostini P, Cuneo A, Castoldi G, Baricordi O, Di Virgilio FA. His-155 to Tyr polymorphism confers gain-of-function to the human P2X7 receptor of human leukemic lymphocytes. J Immunol. 2005;175:82-9. (Pubitemid 40884304)
61. Sluyter R, Shemon AN, Wiley JS. Glu496 to Ala polymorphism in the P2X7 receptor impairs ATP-induced IL-1 beta release from human monocytes. J Immunol. 2004;172:3399-405. (Pubitemid 38337918)
62. Barden N, Harvey M, Gagné B, Shink E, Tremblay M, Raymond C, Labbé M, Villeneuve A, Rochette D, Bordeleau L, Stadler H, Holsboer F, Müller-Myhsok B. Analysis of single nucleotide polymorphisms in genes in the chromosome 12Q24.31 region points to P2RX7 as a susceptibility gene to bipolar affective disorder. Am J Med Genet B Neuropsychiatr Genet. 2006;141B:374-82.
63. Hejjas K, Szekely A, Domotor E, Halmai Z, Balogh G, Schilling B, Sarosi A, Faludi G, Sasvari-Szekely M, Nemoda Z. Association between depression and the Gln460Arg polymorphism of P2RX7 gene: a dimensional approach. Am J Med Genet B Neuropsychiatr Genet. 2009;150B:295-9.
64. Grigoroiu-Serbanescu M, Herms S, Mühleisen T, Georgi A, Diaconu C, Strohmaier J, Czerski P, Hauser J, Leszczynska- Rodziewicz A, Jamra R, Babadjanova G, Tiganov A, Krasnov V, Kapiletti S, Neagu A, Vollmer J, Breuer R, Rietschel M, Nöthen M, Cichon S, Propping P. Variation in P2RX7 candidate gene (rs2230912) is not associated with bipolar I disorder and unipolar major depression in four European samples. Am J Med Genet B Neuropsychiatr Genet. 2009;150B:1017-21.
65. McQuillin A, Bass N, Choudhury K, Puri V, Kosmin M, Lawrence J, Curtis D, Gurling H. Case-control studies show that a non-conservative amino-acid change from a glutamine to arginine in the P2RX7 purinergic receptor protein is associated with both bipolar- and unipolar-affective disorders. Mol Psychiatry. 2009;14:614-20.
66. Denlinger LC, Coursin D, Schell K, Angelini G, Green D, Guadarrama AG, Halsey J, Prabhu U, Hogan K, Bertics PJ. Human P2X7 pore function predicts allele linkage disequilibrium. Clin Chem. 2006;52:995-1004. (Pubitemid 43794409)
67. Jamieson SE, Peixoto-Rangel AL, Hargrave AC, Roubaix LA, Mui EJ, Boulter NR, Miller EN, Fuller SJ, Wiley JS, Castellucci L, Boyer K, Peixe RG, Kirisits MJ, LeS Elias, Coyne JJ, Correa- Oliveira R, Sautter M, Smith NC, Lees MP, Swisher CN, Heydemann P, Noble AG, Patel D, Bardo D, Burrowes D, McLone D, Roizen N, Withers S, Bahia-Oliveira LM, McLeod R, Blackwell JM. Evidence for associations between the purinergic receptor P2X(7) (P2RX7) and toxoplasmosis. Genes Immun. 2010;11:374-83.
68. Denlinger LC, Angelini G, Schell K, Green D, Guadarrama AG, Prabhu U, Coursin D, Bertics PJ, Hogan K. Detection of human P2X7 nucleotide receptor polymorphisms by a novel monocyte pore assay predictive of alterations in lipopolysaccharideinduced cytokine production. J Immunol. 2005;174:4424-31. (Pubitemid 40396026)
69. Carroll WA, Donnelly-Roberts D, Jarvis MF. Selective P2X(7) receptor antagonists for chronic inflammation and pain. Purinergic Signal. 2009;5:63-73.
70. ClinicalTrials.gov Home Page. http://www.clinicaltrials.gov (Accessed 2 Jan, 2011).
71. Pfizer Pipeline. http://media.pfizer.com/files/research/pipeline/ 2008-0930/pipeline-2008-0930.pdf (Accessed 2 Jan , 2011).
72. Affectis Pharmaceuticals AG Home Page. http://www.affectis. com (accessed January 2, 2011).
73. Affectis Pharmaceuticals AG. http://www.affectis.com/attach ments/011-Affectis%20-%20Patent%20Update-02Apr09.pdf (accessed January 2, 2011).
74. Amin S. Mechanical factors and bone health: effects of weightlessness and neurologic injury. Curr Rheumatol Rep. 2010;12: 170-6.
75. Ohlendorff SD, Tofteng CL, Jensen JE, Petersen S, Civitelli R, Fenger M, Abrahamsen B, Hermann AP, Eiken P, Jørgensen NR, Jrgensen NR. Single nucleotide polymorphisms in the P2X7 gene are associated to fracture risk and to effect of estrogen treatment. Pharmacogenet Genomics. 2007;17:555-67. (Pubitemid 46905222)
76. Ferrari D, Pizzirani C, Adinolfi E, Lemoli R, Curti A, Idzko M, Panther E, Di Virgilio F. The P2X7 receptor: a key player in IL-1 processing and release. J Immunol. 2006;176:3877-83. (Pubitemid 44264361)
77. Griffin WS. Inflammation and neurodegenerative diseases. Am J Clin Nutr. 2006;83:470S-4S.
78. Qu Y, Franchi L, Nunez G, Dubyak GR. Nonclassical IL-1 beta secretion stimulated by P2X7 receptors is dependent on in- flammasome activation and correlated with exosome release in murine macrophages. J Immunol. 2007;179:1913-25.
79. Di Virgilio F. Liaisons dangereuses: P2X(7) and the inflammasome. Trends Pharmacol Sci. 2007;28:465-72.
80. Takenouchi T, Sugama S, Iwamaru Y, Hashimoto M, Kitani H. Modulation of the ATP-lnduced release and processing of IL-1beta in microglial cells. Crit Rev Immunol. 2009;29:335-45.
81. Labasi JM, Petrushova N, Donovan C, McCurdy S, Lira P, Payette MM, Brissette W, Wicks JR, Audoly L, Gabel CA. Absence of the P2X7 receptor alters leukocyte function and attenuates an inflammatory response. J Immunol. 2002;168: 6436-45. (Pubitemid 34620068)
82. Elssner A, Duncan M, Gavrilin M, Wewers MD. A novel P2X7 receptor activator, the human cathelicidin-derived peptide LL37, induces IL-1 beta processing and release. J Immunol. 2004;172: 4987-94. (Pubitemid 38456425)
83. Pelegrin P, Surprenant A. Pannexin-1 mediates large pore formation and interleukin-1beta release by the ATP-gated P2X7 receptor. The EMBO J. 2006;25:5071-82. (Pubitemid 44658525)
84. Pelegrin P, Barroso-Gutierrez C, Surprenant A. P2X7 receptor differentially couples to distinct release pathways for IL-1beta in mouse macrophage. J Immunol. 2008;180:7147-57.
85. Al-Shukaili A, Al-Kaabi J, Hassan B. A comparative study of interleukin-1beta production and p2x7 expression after ATP stimulation by peripheral blood mononuclear cells isolated from rheumatoid arthritis patients and normal healthy controls. Inflammation. 2008;31:84-90. (Pubitemid 351388891)
86. Griffin WS, Sheng JG, Royston MC, Gentleman SM, McKenzie JE, Graham DI, Roberts GW, Mrak RE. Glial-neuronal interactions in Alzheimer's disease: the potential role of a 'cytokine cycle' in disease progression. Brain Pathol. 1998;8:65-72.
87. Parvathenani LK, Tertyshnikova S, Greco CR, Roberts SB, Robertson B, Posmantur R. P2X7 mediates superoxide production in primary microglia and is up-regulated in a transgenic mouse model of Alzheimer's disease. J Biol Chem. 2003;278: 13309-17. (Pubitemid 36800102)
88. Bernardino L, Balosso S, Ravizza T, Marchi N, Ku G, Randle JC, Malva JO, Vezzani A. Inflammatory events in hippocampal slice cultures prime neuronal susceptibility to excitotoxic injury: a crucial role of P2X7 receptor-mediated IL-1beta release. J Neurochem. 2008;106:271-80. (Pubitemid 351840213)
89. Guerra AN, Gavala ML, Chung HS, Bertics PJ. Nucleotide receptor signalling and the generation of reactive oxygen species. Purinergic Signal. 2007;3:39-51.
90. Pfeiffer ZA, Guerra AN, Hill LM, Gavala ML, Prabhu U, Aga M, Hall DJ, Bertics PJ. Nucleotide receptor signaling in murine macrophages is linked to reactive oxygen species generation. Free Radical Biol & Med. 2007;42:1506-16. (Pubitemid 46590610)
91. Mingam R, De Smedt V, Amédée T, Bluthé RM, Kelley KW, Dantzer R, Layé S. In vitro and in vivo evidence for a role of the P2X7 receptor in the release of IL-1 beta in the murine brain. Brain Behav Immun. 2008;22:234-44.
92. Ballerini P, Ciccarelli R, Caciagli F, Rathbone MP, Werstiuk ES, Traversa U, Buccella S, Giuliani P, Jang S, Nargi E, Visini D, Santavenere C, Di Iorio P. P2X7 receptor activation in rat brain cultured astrocytes increases the biosynthetic release of cysteinyl leukotrienes. Int J Immunopathol Pharmacol. 2005;18: 417-30. (Pubitemid 41532358)
93. Bianco F, Colombo A, Saglietti L, Lecca D, Abbracchio MP, Matteoli M, Verderio C. Different properties of P2X(7) receptor in hippocampal and cortical astrocytes. Purinergic Signal. 2009;5:233-40.
94. Lee SC, Liu W, Dickson DW, Brosnan CF, Berman JW. Cytokine production by human fetal microglia and astrocytes. Differential induction by lipopolysaccharide and IL-1 beta. J Immunol. 1993;150:2659-67. (Pubitemid 23127515)
95. Narcisse L, Scemes E, Zhao Y, Lee SC, Brosnan CF. The cytokine IL-1beta transiently enhances P2X7 receptor expression and function in human astrocytes. Glia. 2005;49:245-58. (Pubitemid 40188503)
96. Brough D, Le Feuvre RA, Iwakura Y, Rothwell NJ. Purinergic (P2X7) receptor activation of microglia induces cell death via an interleukin-1- independent mechanism. Mol Cell Neurosci. 2002; 19:272-80. (Pubitemid 34211906)
97. Hughes J, Hatcher J, Chessell I. The role of P2X(7) in pain and inflammation. Purinergic Signal. 2007;3:163-9.
98. Hu Y, Fisette PL, Denlinger LC, Guadarrama AG, Sommer JA, Proctor RA, Bertics PJ. Purinergic receptor modulation of lipopolysaccharide signaling and inducible nitric-oxide synthase expression in RAW 264.7 macrophages. J Biol Chem. 1998;273: 27170-5. (Pubitemid 28500425)
99. Wei W, Ryu J, Choi H, McLarnon J. Expression and function of the P2X(7) receptor in rat C6 glioma cells. Cancer Lett. 2008;260:79-87.
100. Yip L, Woehrle T, Corriden R, Hirsh M, Chen Y, Inoue Y, Ferrari V, Insel PA, Junger WG. Autocrine regulation of T-cell activation by ATP release and P2X7 receptors. FASEB J. 2009; 23:1685-93.
101. Kataoka A, Tozaki-Saitoh H, Koga Y, Tsuda M, Inoue K. Activation of P2X7 receptors induces CCL3 production in microglial cells through transcription factor NFAT. J Neurochem. 2009;108:115-25.
102. Aga M, Watters JJ, Pfeiffer ZA, Wiepz GJ, Sommer JA, Bertics PJ. Evidence for nucleotide receptor modulation of cross talk between MAP kinase and NF-kappa B signaling pathways in murine RAW 264.7 macrophages. Am J Physiol Cell Physiol. 2004;286:C923-30.
103. Friedle S, Brautigam V, Nikodemova M, Wright M, Watters JJ. The P2X7-Egr pathway regulates nucleotide-dependent inflammatory gene expression in microglia. Glia. 2011;59:1-13.
104. Stefano L, Rössler OG, Griesemer D, Hoth M, Thiel G. P2X(7) receptor stimulation upregulates Egr-1 biosynthesis involving a cytosolic Ca(2+) rise, transactivation of the EGF receptor and phosphorylation of ERK and Elk-1. J Cell Physiol. 2007;213:36-44.
105. Olsson AK, Dimberg A, Kreuger J, Claesson-Welsh L. VEGF receptor signalling - in control of vascular function. Nat Rev Mol Cell Biol. 2006;7:359-71.
106. Dineen SP, Lynn KD, Holloway SE, Miller AF, Sullivan JP, Shames DS, Beck AW, Barnett CC, Fleming JB, Brekken RA. Vascular endothelial growth factor receptor 2 mediates macrophage infiltration into orthotopic pancreatic tumors in mice. Cancer Res. 2008;68:4340-6.
107. Thi MM, Suadicani SO, Spray DC. Fluid flow-induced soluble vascular endothelial growth factor isoforms regulate actin adaptation in osteoblasts. J Biol Chem. 2010;285:30931-41.
108. Kobayashi Y. The role of chemokines in neutrophil biology. Front Biosci. 2008;13:2400-7. (Pubitemid 351599693)
109. Idzko M, Panther E, Bremer HC, Sorichter S, Luttmann W, Virchow CJ, Di Virgilio F, Herouy Y, Norgauer J, Ferrari D. Stimulation of P2 purinergic receptors induces the release of eosinophil cationic protein and interleukin-8 from human eosinophils. Br J Pharmacol. 2003;138:1244-50. (Pubitemid 36543121)
110. Schneider EM, Vorlaender K, Ma X, Du W, Weiss M. Role of ATP in trauma-associated cytokine release and apoptosis by P2X7 ion channel stimulation. Ann N Y Acad Sci. 2006;1090:245-52. (Pubitemid 47092129)
111. McDonald B, Pittman K, Menezes GB, Hirota SA, Slaba I, Waterhouse CC, Beck PL, Muruve DA, Kubes P. Intravascular danger signals guide neutrophils to sites of sterile inflammation. Science. 2010;330:362-6.
112. Malek TR, Castro I. Interleukin-2 receptor signaling: at the interface between tolerance and immunity. Immunity. 2010;33:153-65.
113. Novak K. Swinging the vote for rapamycin. Nat Rev Cancer. 2002;2:75.
114. Sun M, Lughezzani G, Perrotte P, Karakiewicz PI. Treatment of metastatic renal cell carcinoma. Nat Rev Urol. 2010;7:327-38.
115. Tawbi H, Nimmagadda N. Targeted therapy in melanoma. Biologics. 2009;3:475-84.
116. Budagian V, Bulanova E, Brovko L, Orinska Z, Fayad R, Paus R, Bulfone-Paus S. Signaling through P2X7 receptor in human T cells involves p56lck, MAP kinases, and transcription factors AP-1 and NF-kappa B. J Biol Chem. 2003;278:1549-60. (Pubitemid 36801383)
117. Woehrle T, Yip L, Manohar M, Sumi Y, Yao Y, Chen Y, Junger WG. Hypertonic stress regulates T cell function via pannexin-1 hemichannels and P2X receptors. J Leukoc Biol. 2010;88:1181-9.
118. Guzik TJ, Korbut R, Adamek-Guzik T. Nitric oxide and superoxide in inflammation and immune regulation. J Physiol Pharmacol. 2003;54:469-87. (Pubitemid 38029745)
119. Gendron FP, Chalimoniuk M, Strosznajder J, Shen S, González FA, Weisman GA, Sun GY. P2X7 nucleotide receptor activation enhances IFN gamma-induced type II nitric oxide synthase activity in BV-2 microglial cells. J Neurochem. 2003;87:344-52. (Pubitemid 37255242)
120. Kusner D, Adams J. ATP-induced killing of virulent Mycobacterium tuberculosis within human macrophages requires phospholipase D. J Immunol. 2000;164:379-88. (Pubitemid 30013012)
121. Cha Y, Solnica-Krezel L, DuBois R. Fishing for prostanoids: deciphering the developmental functions of cyclooxygenase-derived prostaglandins. Dev Biol. 2006;289:263-72. (Pubitemid 43049931)
122. Blackwell KA, Raisz LG, Pilbeam CC. Prostaglandins in bone: bad cop, good cop? Trends Endocrinol Metab. 2010;21:294-301.
123. Panupinthu N, Rogers JT, Zhao L, Solano-Flores LP, Possmayer F, Sims SM, Dixon SJ. P2X7 receptors on osteoblasts couple to production of lysophosphatidic acid: a signaling axis promoting osteogenesis. J Cell Biol. 2008;181:859-71. (Pubitemid 351786989)
124. Takayanagi H. Osteoimmunology : shared mechanisms and crosstalk between the immune and bone systems. Nat Rev Immunol. 2007;7:292-304. (Pubitemid 46480961)
125. McCoy JM, Wicks JR, Audoly LP. The role of prostaglandin E2 receptors in the pathogenesis of rheumatoid arthritis. J Clin Invest. 2002;110:651-8. (Pubitemid 34988789)
126. Gómez-Martín D, Díaz-Zamudio M, Galindo-Campos M, Alcocer-Varela J. Early growth response transcription factors and the modulation of immune response: implications towards autoimmunity. Autoimmun Rev. 2010;9:454-8.
127. Shimoyamada H, Yazawa T, Sato H, Okudela K, Ishii J, Sakaeda M, Kashiwagi K, Suzuki T, Mitsui H, Woo T, Tajiri M, Ohmori T, Ogura T, Masuda M, Oshiro H, Kitamura H. Early growth response-1 induces and enhances vascular endothelial growth factor-A expression in lung cancer cells. Am J Pathol. 2010;177:70-83.
128. Mancini M, Toker A. NFAT proteins: emerging roles in cancer progression. Nat Rev Cancer. 2009;9:810-20.
129. Gwack Y, Feske S, Srikanth S, Hogan PG, Rao A. Signalling to transcription: store-operated Ca2+ entry and NFAT activation in lymphocytes. Cell Calcium. 2007;42:145-56. (Pubitemid 47029605)
130. Adinolfi E, Callegari MG, Cirillo M, Pinton P, Giorgi C, Cavagna D, Rizzuto R, Di Virgilio F. Expression of the P2X7 receptor increases the Ca2+ content of the endoplasmic reticulum, activates NFATc1, and protects from apoptosis. J Biol Chem. 2009;284:10120-8.
131. Ferrari D, Stroh C, Schulze-Osthoff K. P2X7/P2Z purinoreceptor-mediated activation of transcription factor NFAT in microglial cells. J Biol Chem. 1999;274:13205-10.
132. Wang S, Liu Z, Wang L, Zhang X. NF-kappaB signaling pathway, inflammation and colorectal cancer. Cell Mol Immunol. 2009;6:327-34.
133. Luqman S, Pezzuto JM. NFkappaB a promising target for natural products in cancer chemoprevention. Phytother Res. 2010;24:949-63.
134. Ferrari D, Wesselborg S, Bauer MK, Schulze-Osthoff K. Extracellular ATP activates transcription factor NF-kappaB through the P2Z purinoreceptor by selectively targeting NF-kappaB p65. J Cell Biol. 1997;139:1635-43. (Pubitemid 28079229)
135. Korcok J, Raimundo LN, Ke HZ, Sims SM, Dixon SJ. Extracellular nucleotides act through P2X7 receptors to activate NF-kappaB in osteoclasts. J Bone Miner Res. 2004;19:642-51. (Pubitemid 41071225)
136. Wen AY, Sakamoto KM, Miller LS. The role of the transcription factor CREB in immune function. J Immunol. 2010;185:6413-9.
137. Potucek YD, Crain JM, Watters JJ. Purinergic receptors modulate MAP kinases and transcription factors that control microglial inflammatory gene expression. Neurochem Int. 2006;49:204-14. (Pubitemid 43867079)
138. Milde-Langosch K. The Fos family of transcription factors and their role in tumourigenesis. Eur J Cancer. 2005;41:2449-61. (Pubitemid 41540622)
139. Padeh S, Cohen A, Roifman CM. ATP-induced activation of human B lymphocytes via P2-purinoceptors. J Immunol. 1991; 146:1626-32.
140. Nestler EJ, Barrot M, Self DW. DeltaFosB: a sustained molecular switch for addiction. Proc Natl Acad Sci USA. 2001;98:11042-6. (Pubitemid 32928680)
141. Nakabeppu Y, Nathans D. A naturally occurring truncated form of FosB that inhibits Fos/Jun transcriptional activity. Cell. 1991;64:751-9. (Pubitemid 121001162)
142. Carle T, Ohnishi Y, Ohnishi Y, Alibhai I, Wilkinson M, Kumar A, Nestler E. Proteasome-dependent and -independent mechanisms for FosB destabilization: identification of FosB degron domains and implications for DeltaFosB stability. Eur J Neurosci. 2007;25:3009-19. (Pubitemid 46888818)
143. McClung C, Ulery P, Perrotti L, Zachariou V, Berton O, Nestler E. DeltaFosB: a molecular switch for long-term adaptation in the brain. Brain Res Mol Brain Res. 2004;132:146-54. (Pubitemid 39586757)
144. Greenwood BN, Foley TE, Le TV, Strong PV, Loughridge AB, Day HE, Fleshner M. Long-term voluntary wheel running is rewarding and produces plasticity in the mesolimbic reward pathway. Behav Brain Res. 2010;217:354-62.
145. Hope BT, Nye HE, Kelz MB, Self DW, Iadarola MJ, Nakabeppu Y, Duman RS, Nestler EJ. Induction of a long-lasting AP-1 complex composed of altered Fos-like proteins in brain by chronic cocaine and other chronic treatments. Neuron. 1994;13:1235-44. (Pubitemid 24372141)
146. Nye HE, Nestler EJ. Induction of chronic Fos-related antigens in rat brain by chronic morphine administration. Mol Pharmacol. 1996;49:636-45. (Pubitemid 26117147)
147. Pich EM, Pagliusi SR, Tessari M, Talabot-Ayer D, Hooft van Huijsduijnen R, Chiamulera C. Common neural substrates for the addictive properties of nicotine and cocaine. Science. 1997;275:83-6. (Pubitemid 27020313)
148. Werme M, Messer C, Olson L, Gilden L, Thorén P, Nestler EJ, Brené S. Delta FosB regulates wheel running. J Neurosci. 2002;22:8133-8. (Pubitemid 35379119)
149. Wallace DL, Vialou V, Rios L, Carle-Florence TL, Chakravarty S, Kumar A, Graham DL, Green TA, Kirk A, Iñiguez SD, Perrotti LI, Barrot M, DiLeone RJ, Nestler EJ, Bolaños-Guzmán CA. The influence of DeltaFosB in the nucleus accumbens on natural reward-related behavior. J Neurosci. 2008;28:10272-7.
150. Brown J, Ye H, Bronson R, Dikkes P, Greenberg M. A defect in nurturing in mice lacking the immediate early gene fosB. Cell. 1996;86:297-309. (Pubitemid 26286112)
151. Hiroi N, Brown JR, Haile CN, Ye H, Greenberg ME, Nestler EJ. FosB mutant mice: loss of chronic cocaine induction of Fos-related proteins and heightened sensitivity to cocaine's psychomotor and rewarding effects. Proc Natl Acad Sci USA. 1997;94:10397-402. (Pubitemid 27407053)
152. Zachariou V, Bolanos CA, Selley DE, Theobald D, Cassidy MP, Kelz MB, Shaw-Lutchman T, Berton O, Sim-Selley LJ, Dileone RJ, Kumar A, Nestler EJ. An essential role for DeltaFosB in the nucleus accumbens in morphine action. Nat Neurosci. 2006;9:205-11. (Pubitemid 43164543)
153. Kelz MB, Chen J, Carlezon WA, Whisler K, Gilden L, Beckmann AM, Steffen C, Zhang YJ, Marotti L, Self DW, Tkatch T, Baranauskas G, Surmeier DJ, Neve RL, Duman RS, Nestler EJ, Picciotto MR. Expression of the transcription factor deltaFosB in the brain controls sensitivity to cocaine. Nature. 1997;401:272-6.
154. Gharib S, Liles W, Klaff L, Altemeier W. Noninjurious mechanical ventilation activates a proinflammatory transcriptional program in the lung. Physiol Genomics. 2009;37:239-48.
155. Luis-Delgado O, Barrot M, Rodeau J, Ulery P, Freund-Mercier M, Lasbennes F. The transcription factor DeltaFosB is recruited by inflammatory pain. J Neurochem. 2006;98:1423-31. (Pubitemid 44200434)
156. Chaum E, Yin J, Yang H, Thomas F, Lang J. Quantitative AP-1 gene regulation by oxidative stress in the human retinal pigment epithelium. J Cell Biochem. 2009;108:1280-91.
157. Bièche I, Lerebours F, Tozlu S, Espie M, Marty M, Lidereau R. Molecular profiling of inflammatory breast cancer: identification of a poor-prognosis gene expression signature. Clin Cancer Res. 2004;10:6789-95. (Pubitemid 39383027)
158. Gruda MC, van Amsterdam J, Rizzo CA, Durham SK, Lira S, Bravo R. Expression of FosB during mouse development: normal development of FosB knockout mice. Oncogene. 1996;12:2177-85. (Pubitemid 26168427)
159. Sabatakos G, Sims NA, Chen J, Aoki K, Kelz MB, Amling M, Bouali Y, Mukhopadhyay K, Ford K, Nestler EJ, Baron R. Overexpression of DeltaFosB transcription factor(s) increases bone formation and inhibits adipogenesis. Nat Med. 2000;6:985-90.
160. Kido S, Kuriwaka-Kido R, Imamura T, Ito Y, Inoue D, Matsumoto T. Mechanical stress induces Interleukin-11 expression to stimulate osteoblast differentiation. Bone. 2009;45:1125-32.
161. Suga K, Saitoh M, Fukushima S, Takahashi K, Nara H, Yasuda S, Yasuda S, Miyata K. Interleukin-11 induces osteoblast differentiation and acts synergistically with bone morphogenetic protein-2 in C3H10T1/2 cells. J Interferon Cytokine Res. 2001;21:695-707. (Pubitemid 32955700)
162. Gleave RJ, Walter DS, Beswick PJ, Fonfria E, Michel AD, Roman SA, Tang SP. Synthesis and biological activity of a series of tetrasubstituted-imidazoles as P2X(7) antagonists. Bioorg Med Chem Lett. 2010;20:4951-4.
163. Chambers LJ, Stevens AJ, Moses AP, Michel AD, Walter DS, Davies DJ, Livermore DG, Fonfria E, Demont EH, Vimal M, Theobald PJ, Beswick PJ, Gleave RJ, Roman SA, Senger S. Synthesis and structure-activity relationships of a series of (1H-pyrazol-4-yl)acetamide antagonists of the P2X7 receptor. Bioorg Med Chem Lett. 2010;20:3161-4.
164. Chen X, Pierce B, Naing W, Grapperhaus ML, Phillion DP. Discovery of 2-chloro-N-((4, 4-difluoro-1-hydroxycyclohexyl) methyl)-5-(5-fluoropyrimidin-2- yl)benzamide as a potent and CNS penetrable P2X7 receptor antagonist. Bioorg Med Chem Lett. 2010;20:3107-11.
165. Lee JY, Yu J, Cho WJ, Ko H, Kim YC. Synthesis and structure-activity relationships of pyrazolodiazepine derivatives as human P2X7 receptor antagonists. Bioorg Med Chem Lett. 2009;19:6053-8.
166. Lee G, Joshi B, Chen W, Jeong L, Moon H, Jacobson K, Kim Y. Synthesis and structure-activity relationship studies of tyrosine-based antagonists at the human P2X7 receptor. Bioorg Med Chem Lett. 2008;18:571-5.
167. Berton O, Covington HE, Ebner K, Tsankova NM, Carle TL, Ulery P, Bhonsle A, Barrot M, Krishnan V, Singewald GM, Singewald N, Birnbaum S, Neve RL, Nestler EJ. Induction of deltaFosB in the periaqueductal gray by stress promotes active coping responses. Neuron. 2007;55:289-300. (Pubitemid 47048913)
168. Gu B, Sluyter R, Skarratt K, Shemon A, Dao-Ung L, Fuller S, Barden J, Clarke A, Petrou S, Wiley J. An Arg307 to Gln polymorphism within the ATP-binding site causes loss of function of the human P2X7 receptor. J Biol Chem. 2004;279:31287-95. (Pubitemid 39037794)
169. Wiley J, Dao-Ung L, Li C, Shemon A, Gu B, Smart M, Fuller S, Barden J, Petrou S, Sluyter R. An Ile-568 to Asn polymorphism prevents normal trafficking and function of the human P2X7 receptor. J Biol Chem. 2003;278:17108-13.